1. Epigenetics
  2. AMPK

YLF-466D (Synonyms: C24)

Cat. No.: HY-15840 Purity: 99.16%
Handling Instructions

YLF-466D is a newly developed AMPK activator, which inhibits platelet aggregation.

For research use only. We do not sell to patients.
YLF-466D Chemical Structure

YLF-466D Chemical Structure

CAS No. : 1273323-67-3

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 462 In-stock
5 mg USD 420 In-stock
10 mg USD 600 In-stock
50 mg USD 1800 In-stock
100 mg USD 2520 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

    YLF-466D purchased from MCE. Usage Cited in: Eur J Pharmacol. 2015 Apr 22;760:81-87.

    YLF-466D induces VASP phosphorylation by activating AMPK. (A) Phosphorylation of VASP by YLF-466D (YLF) and (B) its prevention by AMPK inhibitors. WP is treated with CC, ara-A and YLF-466D. Phosphorylation of VASP at Ser239 and Ser157 are measured by immunoblotting with phospho-specific antibodies.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References


    YLF-466D is a newly developed AMPK activator, which inhibits platelet aggregation.

    IC50 & Target


    In Vitro

    The effect of YLF-466D on platelet AMPK and aggregation are examined to test whether YLF-466D can stimulate AMPK in platelets and thereby suppress aggregation. Platelet AMPK is activated by YLF-466D, which is confirmed with activation-dependent phosphorylation at Thr172. Consistent with this result, YLF-466D inhibits platelet aggregation induced by thrombin. Such inhibition is observed in the aggregation elicited by ADP and collagen as well as thrombin, indicating that the antiaggregatory effect of YLF-466D is not platelet-agonist specific but common, regardless of agonist type. All the effects on AMPK and aggregation are concentration-dependent with the highest efficacy at 150 μM. IC50 against thrombin-, ADP- and collagen-induced aggreation are approximately 84, 55 and 87 μM, respectively[1].

    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 2.1462 mL 10.7312 mL 21.4625 mL
    5 mM 0.4292 mL 2.1462 mL 4.2925 mL
    10 mM 0.2146 mL 1.0731 mL 2.1462 mL
    Please refer to the solubility information to select the appropriate solvent.
    Kinase Assay

    Blood is collected from the abdominal aorta of ether anesthetized rats using 3.2% sodium citrate as an anticoagulant (sodium citrate:blood=1:9) and diluted with normal saline (1:1). Blood is incubated with YLF-466D (0, 50, 100 and 150 μM) for 3 min and aggregation is induced with 7.5 μg/mL Collagen. Aggregation is assessed by measuring the impedance change with a whole blood aggregometer[1].
    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight




    CAS No.




    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Purity: 99.16%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cat. No.: